56 related articles for article (PubMed ID: 9988223)
1. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease.
Braun S; Hepp F; Sommer HL; Pantel K
Int J Cancer; 1999 Feb; 84(1):1-5. PubMed ID: 9988223
[TBL] [Abstract][Full Text] [Related]
2. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.
Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S
Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387
[TBL] [Abstract][Full Text] [Related]
3. Plant Recycling for Molecular Biofarming to Produce Recombinant Anti-Cancer mAb.
Kim DS; Song I; Kim J; Kim DS; Ko K
Front Plant Sci; 2016; 7():1037. PubMed ID: 27486465
[TBL] [Abstract][Full Text] [Related]
4. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.
Guo ZS; Lotze MT; Zhu Z; Storkus WJ; Song XT
Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32664210
[TBL] [Abstract][Full Text] [Related]
5. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion.
Wang H; Stoecklein NH; Lin PP; Gires O
Oncotarget; 2017 Jan; 8(1):1884-1912. PubMed ID: 27683128
[TBL] [Abstract][Full Text] [Related]
6. Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.
Joshi P; Jacobs B; Derakhshan A; Moore LR; Elson P; Triozzi PL; Borden E; Zborowski M
Oncotarget; 2014 May; 5(9):2450-61. PubMed ID: 24811334
[TBL] [Abstract][Full Text] [Related]
7. The role and clinical relevance of disseminated tumor cells in breast cancer.
Banys M; Krawczyk N; Fehm T
Cancers (Basel); 2014 Jan; 6(1):143-52. PubMed ID: 24434543
[TBL] [Abstract][Full Text] [Related]
8. Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study.
Luyckx V; Durant JF; Camboni A; Gilliaux S; Amorim CA; Van Langendonckt A; Irenge LM; Gala JL; Donnez J; Dolmans MM
J Assist Reprod Genet; 2013 Oct; 30(10):1289-99. PubMed ID: 23989997
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells.
Jain J; Veggiani G; Howarth M
Cancer Res; 2013 Apr; 73(7):2310-21. PubMed ID: 23378340
[TBL] [Abstract][Full Text] [Related]
10. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
[TBL] [Abstract][Full Text] [Related]
11. Emerging technologies for CTC detection based on depletion of normal cells.
Lustberg M; Jatana KR; Zborowski M; Chalmers JJ
Recent Results Cancer Res; 2012; 195():97-110. PubMed ID: 22527498
[TBL] [Abstract][Full Text] [Related]
12. The interrelating dynamics of hypoxic tumor microenvironments and cancer cell phenotypes in cancer metastasis.
Bartkowiak K; Riethdorf S; Pantel K
Cancer Microenviron; 2012 Apr; 5(1):59-72. PubMed ID: 21626313
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
[TBL] [Abstract][Full Text] [Related]
14. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
Boskovitz A; McLendon RE; Okamura T; Sampson JH; Bigner DD; Zalutsky MR
Nucl Med Biol; 2009 Aug; 36(6):659-69. PubMed ID: 19647172
[TBL] [Abstract][Full Text] [Related]
15. Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells.
Balasubramanian P; Yang L; Lang JC; Jatana KR; Schuller D; Agrawal A; Zborowski M; Chalmers JJ
Mol Pharm; 2009; 6(5):1402-8. PubMed ID: 19445481
[TBL] [Abstract][Full Text] [Related]
16. Cancer micrometastases.
Pantel K; Alix-Panabières C; Riethdorf S
Nat Rev Clin Oncol; 2009 Jun; 6(6):339-51. PubMed ID: 19399023
[TBL] [Abstract][Full Text] [Related]
17. Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.
Fehm T; Müller V; Alix-Panabières C; Pantel K
Breast Cancer Res; 2008; 10 Suppl 1(Suppl 1):S1. PubMed ID: 19091005
[TBL] [Abstract][Full Text] [Related]
18. A "class action" against the microenvironment: do cancer cells cooperate in metastasis?
Bidard FC; Pierga JY; Vincent-Salomon A; Poupon MF
Cancer Metastasis Rev; 2008 Mar; 27(1):5-10. PubMed ID: 18066649
[TBL] [Abstract][Full Text] [Related]
19. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients.
Watson MA; Ylagan LR; Trinkaus KM; Gillanders WE; Naughton MJ; Weilbaecher KN; Fleming TP; Aft RL
Clin Cancer Res; 2007 Sep; 13(17):5001-9. PubMed ID: 17785550
[TBL] [Abstract][Full Text] [Related]
20. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Cabioglu N; Sahin A; Doucet M; Yavuz E; Igci A; O Yildirim E; Aktas E; Bilgic S; Kiran B; Deniz G; Price JE
Clin Exp Metastasis; 2005; 22(1):39-46. PubMed ID: 16132577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
